Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation

Abstract Background Amikacin  liposome inhalation suspension (ALIS) improved sputum culture conversion rate at 6 months for patients with refractory Mycobacterium avium complex pulmonary disease (MAC-PD) in an international phase 3 trial. Patient characteristics and chest high-resolution CT (HRCT) f...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Naohisa Urabe, Susumu Sakamoto, Nozomi Tokita, Hiromichi Yoshida, Yusuke Usui, Hiroshige Shimizu, Muneyuki Sekiya, Shion Miyoshi, Yasuhiko Nakamura, Kazutoshi Isobe, Kazuma Kishi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-09-01
Colecção:	BMC Pulmonary Medicine
Assuntos:	Nontuberculous mycobacterial pulmonary disease; Mycobacterium avium complex; Amikacin liposome inhalation suspension
Acesso em linha:	https://doi.org/10.1186/s12890-024-03261-w
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!